To set up a press or media interview with this expert contact:

Brandie Campbell



Alain Monnereau, MD, PhD, is the Research Program Director and SEER Principal Investigator with the Cancer Registry of Greater California. He is a core member of the leadership group for Public Health Institute’s portfolio of PHI’s cancer research and prevention programs.

His research activities are focused in cancer epidemiology including cancer surveillance, behavioral and environmental risk factors or outcome research (disparities in treatment or survival by socioeconomic status), mainly for hematological malignancies. He has been leading national and international projects on cancer surveillance, prognostic and etiology cancer epidemiology research studies in France, at a European level or international initiatives.

He led the French network of cancer registries while employed in the Comprehensive cancer center in Bordeaux, France, chaired the International Consortium in lymphoma epidemiological research (InterLymph) and has been elected to the European Network of Cancer Registry (ENCR) Steering Committee. He also co-leaded the research program of a cancer epidemiology team labelled by the French National Institute of Health and Medical Research from which he was awarded in 2019. In 2018, his research team was awarded by the caritative organization on Cancer (French League against Cancer).

He is a Medical Doctor from Bordeaux University and received his PhD in epidemiology and public health from Paris-Saclay University.

Work With Us

You change the world. We do the rest. Explore fiscal sponsorship at PHI.

Bring Your Work to PHI

Support Us

Together, we can accelerate our response to public health’s most critical issues.


Find Employment

Begin your career at the Public Health Institute.

See Jobs

Emergency room nurse talks with patient


New Study: ED Buprenorphine Linked to Sustained Opioid Use Disorder Treatment

Patients who get their first dose of buprenorphine in the Emergency Department (ED) are more likely to remain engaged in opioid use disorder treatment 30 days post-discharge, finds a new study from PHI's CA Bridge—reinforcing EDs as critical access points to highly effective, life-saving medication for addiction treatment.

read the study

Continue to